| Description | The antibody LP5 binds to SARS-CoV-2 spike protein. It showed the strongest neutralization activity with an IC50 <0.005 μg/ml against an early SARS-CoV-2 spike gene variant. It binds within the NTD antigenic supersite, The CDR-H2 makes the dominant contribution to antibody recognition by interacting with the NTD loop region N1 (14-26), while the CDR-L3 interacts with the NTD loops N3 (141-156) and N5 (246-260). |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 |
| Epitope | The NTD loops region N1 (14-26), N3 (141-156) and N5 (246-260) |
| Isotype | IgG1 |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA, Neut |
| Application Notes | SARS-CoV-2 spike, RBD, and NTD antigens were coated onto ELISA plates at 2 μg/ml in PBS at room temperature for 2 h. ELISA plates were washed and coated with 100 μl of blocking buffer at RT for 2 h. Purified antibodies were serially diluted using blocking buffer and incubated for 1 h at RT. Plates were washed three times with washing buffer and incubated with a 1:2000 dilution of anti-human kappa light chain detection antibody in blocking buffer at RT for 1 h. Plates were washed with washing buffer and 100 μl Super AquaBlue ELISA substrate was added to each well and incubated before reactions were stopped with 1 M oxalic acid. Absorbance was measured at 405 nm using a BioTek Synergy H1 plate reader. LP5 showed the strongest neutralization activity with an IC50 <0.005 μg/ml against an early SARS-CoV-2 spike gene variant. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Western Blot Protocol |
| Target | SARS-CoV-2 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
